Daly James M 4

What Happened James M. Daly, a director of Madrigal Pharmaceuticals, was awarded equity on 2026-06-17: 454 restricted stock units (RSUs) reported as acquired at $0 and 766 derivative shares reported as acquired at $0 (tied to an option/award). The filing reports no cash purchase — these are compensation awards subject to vesting rather than open‑market buys or sales.

Key Details

• Transaction date(s): 2026-06-17; Form 4 filed 2026-06-18.
• Reported consideration: $0 for both the 454 RSUs and the 766 derivative shares (typical for grants/awards).
• Vesting/conditions: RSUs vest on the earlier of (i) June 17, 2027 or (ii) the issuer’s 2027 annual meeting, contingent on continued service. The 766 derivative/option vests 100% on the same schedule/conditions (see footnotes F1/F2).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing timeliness: Filed the day after the transaction; no late‑filing flag indicated in the information provided.

Context These entries are awards/vesting arrangements (compensation) rather than purchases or sales. Such grants compensate service and retention and do not by themselves indicate a personal market buy or sell decision. The derivative entry reflects a grant/option structure that will convert to common shares only if/when vesting conditions are met.